NG-350A 加放化疗治疗局部晚期直肠癌 (FORTRESS)
NG-350A(一种肿瘤选择性抗 CD40 表达腺病毒载体)联合放化疗治疗局部晚期直肠癌的多中心、开放标签、非随机、1b 期试验 (FORTRESS)
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90033
- University of Southern California
-
-
Florida
-
Orlando、Florida、美国、32804
- AdventHealth Orlando
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
-
Ohio
-
Columbus、Ohio、美国、43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Houston、Texas、美国、77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
London、英国
- University College London NHS FT
-
Sutton、英国
- The Royal Marsden NHS Foundation Trust
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Selected Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the rectum.
- Locally advanced disease (clinical stage II-III based on pelvic MRI) selected by a multidisciplinary team for treatment with neoadjuvant CRT (which may be followed by CNCT to comprise planned TNT). Patients with oligometastatic disease are permitted provided that the site-specific multidisciplinary team deems them suitable for radical treatment/chemoradiation.
- Confirmed microsatellite stable (MSS)/proficient mismatch repair (pMMR) status.
- Provide written informed consent to participate.
- ECOG Performance Status 0 or 1.
- Must not be pregnant or breastfeeding.
- Patients who are sexually active (with either sex) must agree to comply with contraceptive requirements.
- Adequate lung reserve, renal function, hepatic function, and bone marrow/hematological function assessed ≤ 10 days prior to first dose.
Selected Exclusion Criteria:
- Recurrent rectal cancer.
- Distant metastatic disease not amenable to radical treatment/chemoradiation.
- Other prior malignancy active within the previous 3 years, except for local or organ confined early-stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the trial, including response rate and safety.
- Splenectomy (patients with prior partial resection remain eligible if the Investigator considers splenic function to not be significantly compromised).
- Active autoimmune disease that has required systemic therapy in the past 2 years, immunocompromised status in the opinion of the Investigator, or current treatment with systemic immunosuppressive therapy (daily prednisone equivalent for chronic system replacement not to exceed 10mg per day).
- Infectious or inflammatory bowel disease in the 3 months before the first dose of study treatment.
- Any clinically significant cardiovascular, peripheral vascular, cerebrovascular, or thromboembolic event in the last 1 month before the first dose of study treatment.
- Major surgery in the 14 days before the first dose of study treatment or any surgical wounds that are not fully healed and free of infection or dehiscence.
- Any prior surgery for rectal cancer or pelvic radiotherapy.
- Any other anti-cancer or experimental therapy within the previous 12 months or that is planned during the active study treatment period.
- Treatment with any other enadenotucirev-based virus (parent virus or transgene-modified variants), or anti-CD40 antibody at any time.
- History of prior Grade 3-4 acute kidney injury or other clinically significant renal impairment.
- Any ongoing Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 coagulation abnormality/coagulopathy.
URL:
https://www.FortressStudy.org
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:NG-350A 加 CRT 在 12 周积极研究治疗期间
|
a tumour-selective anti-CD40-expressing adenoviral vector chemotherapy long-course intensity-modulated radiotherapy |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
达到缓解的患者比例(ncCR / cCR)
大体时间:在开始使用NG-350A联合放化疗(CRT)后12周
|
在开始使用NG-350A联合放化疗(CRT)后12周
|
次要结果测量
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
根据美国国家癌症研究所不良事件通用术语标准 (NCI CTCAE) v5.0 分级不良事件的发生率和严重程度
大体时间:1-3年
|
1-3年
|
|
临床反应 (CR) 结果
大体时间:开始 NG-350A 联合放化疗 (CRT) 后 12、18 和 36 周
|
开始 NG-350A 联合放化疗 (CRT) 后 12、18 和 36 周
|
|
基于 MRI 的肿瘤消退等级 (mrTRG)
大体时间:开始 NG-350A 联合放化疗 (CRT) 后 12、18 和 36 周
|
开始 NG-350A 联合放化疗 (CRT) 后 12、18 和 36 周
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.